{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:35:33Z","timestamp":1791920133331,"version":"4.3.4"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013302","name":"King Abdullah International Medical Research Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013302","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease with a heterogeneous course that ultimately leads to death. Currently, there is no cure, and new treatments that can slow the progression of the disease are needed. Stem cell (SC) transplantation is an emerging therapy that has shown a lot of potential in recent clinical trials. This review is aimed to examine the results of various clinical trials on this topic, thus assessing the safety and efficacy of SC transplantation as a potential treatment for ALS. We identified 748 studies in our search, of which 134 full-text studies were assessed for eligibility. Six studies met the inclusion criteria and were included in this review. Although some of the included studies showed the positive effect of SC transplantation, other studies found that there was no significant difference compared to the control group. We observed more positive effects with bone marrow mesenchymal stem cells (BM-MSC) treatments than Granulocyte colony-stimulating factor (G-CSF) ones. However, other factors, such as route of administration, number of doses, and number of cells per dose, could also play a role in this discrepancy. Based on this information, we conclude that more properly conducted clinical trials are needed to appreciate the benefit of this treatment.<\/jats:p>","DOI":"10.3389\/fneur.2021.783122","type":"journal-article","created":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T04:42:38Z","timestamp":1638765758000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["The Safety and Efficacy of Stem Cell Therapy as an Emerging Therapy for ALS: A Systematic Review of Controlled Clinical Trials"],"prefix":"10.3389","volume":"12","author":[{"given":"Ammar","family":"Aljabri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alhussain","family":"Halawani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghassan","family":"Bin Lajdam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhail","family":"Labban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samah","family":"Alshehri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razaz","family":"Felemban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,12,1]]},"reference":[{"key":"B1","volume-title":"Amyotrophic Lateral Sclerosis","author":"Brotman","year":"2021"},{"key":"B2","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1007\/s00415-019-09652-y","article-title":"Global variation in prevalence and incidence of amyotrophic lateral sclerosis: a systematic review and meta-analysis","volume":"267","author":"Xu","year":"2020","journal-title":"J Neurol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1111\/ene.14393","article-title":"Amyotrophic lateral sclerosis: a clinical review","volume":"27","author":"Masrori","year":"2020","journal-title":"Euro J Neurol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1016\/S1474-4422(14)70219-4","article-title":"Analysis of amyotrophic lateral sclerosis as a multistep process: A population-based modelling study","volume":"13","author":"Al-Chalabi","year":"2014","journal-title":"Lancet Neurol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1136\/jnnp-2013-305546","article-title":"Genetic counselling in ALS: Facts, uncertainties and clinical suggestions","volume":"85","author":"Chi\u00f2","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B6","volume-title":"Neuropathology E-Book: A Reference Text of CNS Pathology","author":"Ellison","year":"2021"},{"key":"B7","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.bbrc.2006.10.093","article-title":"TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis","volume":"351","author":"Arai","year":"2006","journal-title":"Biochem Biophys Res Commun."},{"key":"B8","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1056\/NEJM199403033300901","article-title":"A controlled trial of riluzole in amyotrophic lateral sclerosis","volume":"330","author":"Bensimon","year":"1994","journal-title":"N Engl J Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2147\/DNND.S135748","article-title":"Riluzole: real-world evidence supports significant extension of median survival times in patients with amyotrophic lateral sclerosis","volume":"7","author":"Hinchcliffe","year":"2017","journal-title":"Degener Neurol Neuromuscul Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"610","DOI":"10.3109\/21678421.2014.959024","article-title":"Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients","volume":"15","author":"Abe","year":"2014","journal-title":"Amyotroph Lateral Scler Front Degener."},{"key":"B11","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S1474-4422(18)30394-6","article-title":"Immune dysregulation in amyotrophic lateral sclerosis: mechanisms and emerging therapies","volume":"18","author":"Beers","year":"2019","journal-title":"Lancet Neurol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1002\/stem.1628","article-title":"Concise review: Stem cell therapies for amyotrophic lateral sclerosis: Recent advances and prospects for the future","volume":"32","author":"Lunn","year":"2014","journal-title":"Stem Cells."},{"key":"B13","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1080\/14653240802644651","article-title":"Stem-cell transplantation into the frontal motor cortex in amyotrophic lateral sclerosis patients","volume":"11","author":"Martinez","year":"2009","journal-title":"Cytotherapy."},{"key":"B14","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3109\/17482960902933809","article-title":"Recombinant human granulocyte-colony stimulating factor administration for treating amyotrophic lateral sclerosis: A pilot study","volume":"11","author":"Nefussy","year":"2010","journal-title":"Amyotrophic Lateral Sclerosis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"164","DOI":"10.3988\/jcn.2015.11.2.164","article-title":"Granulocyte colony-stimulating factor for amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled study of Iranian patients","volume":"11","author":"Amirzagar","year":"2015","journal-title":"J Clin Neurol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1007\/s10517-015-3017-3","article-title":"The use of autologous mesenchymal stem cells for cell therapy of patients with amyotrophic lateral sclerosis in belarus","volume":"159","author":"Rushkevich","year":"2015","journal-title":"Bull Experi Biol Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/ana.25302","article-title":"Repeated intrathecal mesenchymal stem cells for amyotrophic lateral sclerosis","volume":"84","author":"Oh","year":"2018","journal-title":"Ann Neurol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"E2294","DOI":"10.1212\/WNL.0000000000008620","article-title":"NurOwn, phase 2, randomized, clinical trial in patients with ALS: Safety, clinical, and biomarker results","volume":"93","author":"Berry","year":"2019","journal-title":"Neurology."},{"key":"B19","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0022-510X(99)00210-5","article-title":"The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function","volume":"169","author":"Cedarbaum","year":"1999","journal-title":"J Neurol Sci."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1007\/s00415-015-7731-6","article-title":"Predicting prognosis in amyotrophic lateral sclerosis: a simple algorithm","volume":"262","author":"Elamin","year":"2015","journal-title":"J Neurol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1136\/jnnp-2016-314661","article-title":"What does the ALSFRS-R really measure? A longitudinal and survival analysis of functional dimension subscores in amyotrophic lateral sclerosis","volume":"88","author":"Rooney","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41536-021-00131-5","article-title":"Looking backward to move forward: a meta-analysis of stem cell therapy in amyotrophic lateral sclerosis","volume":"6","author":"Morata-Tarifa","year":"2021","journal-title":"NPJ Regene Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/nrneurol.2011.191","article-title":"Translational stem cell therapy for amyotrophic lateral sclerosis","volume":"8","author":"Boulis","year":"2012","journal-title":"Nat Rev Neurol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.3727\/096368909X12483162197123","article-title":"Transient recovery in a rat model of familial amyotrophic lateral sclerosis after transplantation of motor neurons derived from mouse embryonic stem cells","volume":"18","author":"L\u00f3pez-Gonz\u00e1lez","year":"2009","journal-title":"Cell Transplant."},{"key":"B25","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s10072-011-0608-2","article-title":"Bone marrow mesenchymal stem cells can be mobilized into peripheral blood by G-CSF in vivo and integrate into traumatically injured cerebral tissue","volume":"32","author":"Deng","year":"2011","journal-title":"Neurol Sci."},{"key":"B26","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jns.2007.05.016","article-title":"Stem cell treatment in amyotrophic lateral sclerosis","volume":"265","author":"Mazzini","year":"2008","journal-title":"J Neurol Sci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/nri2395","article-title":"Mesenchymal stem cells in health and disease","volume":"8","author":"Uccelli","year":"2008","journal-title":"Nat Rev Immunol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1002\/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C","article-title":"Adult rat and human bone marrow stromal cells differentiate into neurons","volume":"61","author":"Woodbury","year":"2000","journal-title":"J Neurosci Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.expneurol.2004.12.013","article-title":"Neuro-glial differentiation of human bone marrow stem cells in vitro","volume":"193","author":"Bossolasco","year":"2005","journal-title":"Experi Neurol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1001\/jamaneurol.2015.4321","article-title":"Safety and clinical effects of mesenchymal stem cells secreting neurotrophic factor transplantation in patients with amyotrophic lateral sclerosis: results of Phase 1\/2 and 2a clinical trials","volume":"73","author":"Petrou","year":"2016","journal-title":"JAMA Neurol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1212\/WNL.0000000000002889","article-title":"Transplantation of spinal cord-derived neural stem cells for ALS: Analysis of phase 1 and 2 trials","volume":"87","author":"Glass","year":"2016","journal-title":"Neurology."},{"key":"B32","first-page":"592","article-title":"Safety, feasibility of intravenous and intrathecal injection of autologous bone marrow derived mesenchymal stromal cells in patients with amyotrophic lateral sclerosis: An open label phase I clinical trial","volume":"20","author":"Nabavi","year":"2019","journal-title":"Cell J."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/j.neuron.2014.01.013","article-title":"Microglia induce motor neuron death via the classical NF-\u03baB pathway in amyotrophic lateral sclerosis","volume":"81","author":"Frakes","year":"2014","journal-title":"Neuron."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1182\/bloodadvances.2020001711","article-title":"Mesenchymal stromal cell therapeutic potency is dependent upon viability, route of delivery, and immune match","volume":"4","author":"Giri","year":"2020","journal-title":"Blood Adv."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1164\/rccm.201902-0344OC","article-title":"Classifying patients with amyotrophic lateral sclerosis by changes in FVC. A group-based trajectory analysis","volume":"200","author":"Ackrivo","year":"2019","journal-title":"Am J Respir Critical Care Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1136\/jnnp-2013-305770","article-title":"Does surgery accelerate progression of amyotrophic lateral sclerosis?","volume":"85","author":"Pinto","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.783122\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T04:42:46Z","timestamp":1638765766000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.783122\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,1]]},"references-count":36,"alternative-id":["10.3389\/fneur.2021.783122"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2021.783122","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,1]]},"article-number":"783122"}}